Hepato-biliary disorders: isolated asymptomatic hyperbilirubinaemia (total bilirubin ≥ 2.5 mg/ dl, 43 mcmol/ l), reported predominantly as elevated indirect bilirubin and rarely associated with elevations in ALT, AST, or alkaline phosphatase, has occurred in approximately 14% of patients treated with CRIXIVAN alone or in combination with other antiretroviral agents.
Trastornos hepatobiliares: hiperbilirrubinemia asintomática aislada (bilirrubina total ≥ 2,5 mg/ dl, 43 mcmol/ l), notificada de forma predominante como una elevación de la bilirrubina indirecta y asociada en raras ocasiones a elevaciones de ALT, AST o fosfatasa alcalina, en aproximadamente el 14% de los pacientes tratados con CRIXIVAN solo o en combinación con otros agentes antirretrovíricos.